HLA-A and neoplasm: To this end, groups of HLA.A*02+ PBMC-hu-NSG-A2 or -NSG mice (n = 8) were vaccinated with two weekly i.v. injections of F-actin-TNEs loaded with universal tumor-associated HLA-A*02 epitopes (hTERT540–548, Survivin95–104) [33,36] and the HLA Class II promiscuous Survivin97–111 [37].